Oral fumaric acid esters for psoriasis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 4, 2013, Pages

  Atwan, Ausama ^a   Abbott, Rachel ^b   Kelly, Mark J ^a   Pickles, Timothy ^a   Bauer, Andrea ^c   Taylor, Chris ^d   Piguet, Vincent ^a   Ingram, John R ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FUMARIC ACID DERIVATIVE; FUMARIC ACID ESTER; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL PROTOCOL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; LENGTH OF STAY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; QUALITY OF LIFE; SYSTEMATIC REVIEW;

EID: 85031649096     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010497     Document Type: Article

References (31)

1. Augustin M, Ogilvie A. Methods of outcomes measurement in nail psoriasis. Dermatology 2010;221(Suppl 1):23-8. [MEDLINE: 20733312].
2. Basavaraj KH, Ashok NM, Rashmi R, Praveen TK. The role of drugs in the induction and/or exacerbation of psoriasis. International Journal of Dermatology 2010;49(12):1351-61. [MEDLINE: 21091671].
3. Bovenschen HJ, Langewouters AM, van de Kerkhof PC. Dimethylfumarate for psoriasis: Pronounced effects on lesional T-cell subsets, epidermal proliferation and differentiation, but not on natural killer T cells in immunohistochemical study. American Journal of Clinical Dermatology 2010;11(5):343-50.
4. Duffy DL, Spelman LS, Martin NG. Psoriasis in Australian twins. Journal of the American Academy of Dermatology 1993;29(3):428-34. [MEDLINE: 8349859].
5. Eedy DJ, Burrows D, Bridges JM, Jones FG. Clearance of severe psoriasis after allogenic bone marrow transplantation. BMJ 1990;300(6729):908. [MEDLINE: 2337714].
6. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34. [MEDLINE: 9310563].
7. Eghlileb AM, Davies EE, Finlay AY. Psoriasis has a major secondary impact on the lives of family members and partners. British Journal of Dermatology 2007;156(6):1245-50. [MEDLINE: 17459044].
8. García-Caballero M, Marí-Beffa M, Medina MÁ, Quesada AR. Dimethylfumarate inhibits angiogenesis in vitro and in vivo: a possible role for its antipsoriatic effect?. Journal of Investigative Dermatology 2011;131(6):1347-55.
9. Ghoreschi K, Brück J, Kellerer C, Deng C, Peng H, Rothfuss O, et al.Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. Journal of Experimental Medicine 2011;208(11):2291-303.
10. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370(9583):263-71. [MEDLINE: 17658397].
11. Heidenreich R, Rocken M, Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. International Journal of Experimental Pathology 2009;90(3):232-48.
12. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org.
13. Hoefnagel JJ, Thio HB, Willemze R, Bouwes Bavinck JN. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. British Journal of Dermatology 2003;149(2):363-9. [MEDLINE: 12932244].
14. Huerta C, Rivero E, Rodriguez LA. Incidence and risk factors for psoriasis in the general population. Archives of Dermatology 2007;143(12):1559-65. [MEDLINE: 18087008].
15. Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Kremers H. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. Journal of the American Academy of Dermatology 2009;60(3):394-401. [MEDLINE: 19231638].
16. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. American Journal of Clinical Dermatology 2005;6(6):383-92. [MEDLINE: 16343026].
17. Lebwohl M. Psoriasis. Lancet 2003;361(9364):1197-204. [MEDLINE: 12686053].
18. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. European Heart Journal 2010;31(8):1000-6. [MEDLINE: 20037179].
19. Meissner M, Doll M, Hrgovic I, Reichenbach G, König V, Hailemariam-Jahn T, et al.Suppression of VEGFR2 expression in human endothelial cells by dimethylfumarate treatment: evidence for anti-angiogenic action. Journal of Investigative Dermatology 2011;131(6):1356-64.
20. Mrowietz U, Christophers E, Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. British Journal of Dermatology 1999;141(3):424-29. [MEDLINE: 10584060].
21. Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, et al.S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. Journal der Deutschen Dermatologischen Gesellschaft 2012;10(Suppl 2):S1-95.
22. Nestle FO, Kaplan DH, Barker J. Psoriasis. New England Journal of Medicine 2009;361(5):496-509. [MEDLINE: 19641206].
23. O'Rourke K, Detsky AS. Meta-analysis in medical research: strong encouragement for higher quality in individual research efforts. Journal of Clinical Epidemiology 1989;42(10):1021-4. [MEDLINE: 2809651].
24. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM, on behalf of the Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. Journal of Investigative Dermatology 2013;133:377-85. [DOI: 10.1038/jid.2012.339].
25. Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, et al.European S3-Guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology and Venereology 2009;23(Suppl 2):1-70. [MEDLINE: 19712190].
26. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. Journal of the American Academy of Dermatology 1999;41(3 Pt 1):401-7. [MEDLINE: 10459113].
27. Rubant SA, Ludwig RJ, Diehl S, Hardt K, Kaufmann R, Pfeilschifter JM, et al.Dimethylfumarate reduces leukocyte rolling in vivo through modulation of adhesion molecule expression. Journal of Investigative Dermatology 2008;128:326-31.
28. Smith CH, Barker JN. Psoriasis and its management. BMJ 2006;333(7564):380-4. [MEDLINE: 16916825].
29. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, et al.British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. British Journal of Dermatology 2009;161(5):987-1019. [MEDLINE: 19857207].
30. Telfer NR, Chalmers RJ, Whale K, Colman G. The role of streptococcal infection in the initiation of guttate psoriasis. Archives of Dermatology 1992;128(1):39-42. [MEDLINE: 1739285].
31. Warren RB, Kleyn CE, Gulliver WP. Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course. British Journal of Dermatology 2011;164(Suppl 1):1-14. [MEDLINE: 21477010].